Abbott tops earnings estimates, raises outlook as second-half sales ramps up
Abbott Laboratories bumped up its 2026 earnings outlook on Thursday after reporting better-than-expected second-quarter results, thanks mostly to cancer tests and heart devices. Shares jumped almost 4% in early trading. The company left its revenue forecast steady, but now has to deliver second-half growth between about 8.6% and 10.5% to hit its target after putting up 4.3% growth in the first half.